世界の伴侶動物用医薬品市場(~2026年):疾患別(感染症、抗生物質、寄生虫駆除剤、ワクチン、疼痛)、動物種類別(犬、猫、馬)、流通チャネル別(動物病院、クリニック)

◆英語タイトル:Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026
◆商品コード:MD7870
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2029年4月15日
◆ページ数:232
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界の伴侶動物用医薬品市場規模が2021年128億ドルから2026年185億ドルまで、年平均7.6%成長すると予測しています。本調査レポートでは、伴侶動物用医薬品の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業洞察、疾患別(寄生虫駆除剤、皮膚疾患、疼痛、整形外科疾患、行動障害、その他)分析、動物種類別(犬、猫、馬、その他)分析、流通チャネル別(動物病院、動物クリニック、小売薬局)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業洞察
・世界の伴侶動物用医薬品市場規模:疾患別(寄生虫駆除剤、皮膚疾患、疼痛、整形外科疾患、行動障害、その他)
・世界の伴侶動物用医薬品市場規模:動物種類別(犬、猫、馬、その他)
・世界の伴侶動物用医薬品市場規模:流通チャネル別(動物病院、動物クリニック、小売薬局)
・世界の伴侶動物用医薬品市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global companion animal pharmaceuticals market is projected to reach USD 18.5 billion by 2026
from USD 12.8 billion in 2021, at a CAGR of 7.6% during the forecast period.”
Companion animals play an important role in the lives of many, providing a sense of belonging and responsibility. Animal health products, especially pharmaceuticals, are the most widely used products for animal healthcare. They contribute significantly to the health and wellbeing of animals. Companion animal ownership and expenditure have witnessed a significant increase over the years. Pet owners are spending more per pet than ever before. The increasing number of people having pets, emphasis on animal healthcare and vaccination, increasing demand for animal healthcare products, increasing number of veterinary practitioners and their rising income levels in developed economies, increasing prevalence of zoonotic diseases, growth in companion animal adoption, increasing prevalence of animal diseases, and rising demand for pet insurance are some of the factors driving the growth of these markets. However, the limited number of new antibiotics, rising pet care costs, growing resistance to antimicrobials and antibiotics, and rising cost of vaccine storage are restraining the growth of this market to a certain extent.

“The dermatologic diseases segment to grow at the highest CAGR in the companion animal pharmaceuticals market, in the forecast period.”
Based on the prescription of pharmaceuticals for a number of disorders prevailing in animals, the companion animal pharmaceuticals market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic diseases segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of arthritis, rising need for advanced orthopedic drugs, and growing pet population are some of the key factors driving the growth of this segment.

“The dogs segment holds the largest share in the animal type segment, in the forecast period.”
Based on animal type, the companion animal pharmaceuticals market is segmented into dogs, cats, horses, and other companion animals. The dogs segment accounted for the largest market share in 2020. The large share of this segment is attributed to the increasing dog population and rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe.

“Veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market by distribution channel segment in the forecast period”
Based on the distribution channel, the global companion animal pharmaceuticals market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospitals segment is expected to grow at the highest CAGR during the forecast period. The higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries, are some of the key factors driving the growth of this segment.

“North America holds the largest share in the companion animal pharmaceuticals market, by region, in the forecast period”
In 2020, North America accounted for the largest share of the companion animal pharmaceuticals market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the well-established base of animal health industries, the high adoption of companion animals, rising incidence of parasitic infections, the large number of hospitals and clinics, growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is also expected to drive the growth of this market.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America – 3%, Middle East & Africa–2%

The prominent players in the global companion animal pharmaceuticals market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Research Coverage:
The report analyzes the market for various companion animal pharmaceuticals and their adoption pattern. It aims at estimating the market size and future growth potential of the global companion animal pharmaceuticals market and different segments such as indication, animal type, distribution channels, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
• Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market.

【レポートの目次】

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 26
1.2.2 MARKETS COVERED 27
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION 27
1.2.3 YEARS CONSIDERED FOR THE STUDY 27
1.3 CURRENCY 28
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 28
1.4 STAKEHOLDERS 28
1.5 LIMITATIONS 28

2 RESEARCH METHODOLOGY 29
2.1 RESEARCH APPROACH 29
FIGURE 2 RESEARCH DESIGN 29
2.1.1 SECONDARY RESEARCH 30
2.1.1.1 Key data from secondary sources 31
2.1.2 PRIMARY RESEARCH 31
2.1.2.1 Primary sources 32
2.1.2.2 Key data from primary sources 33
2.1.2.3 Key industry insights 34
2.1.2.4 Breakdown of primaries 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 36
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS 36
FIGURE 6 SUPPLY-SIDE ANALYSIS OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 37
FIGURE 7 MARKET ANALYSIS APPROACH 38
FIGURE 8 US: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH 39
FIGURE 9 TOP-DOWN APPROACH 39
FIGURE 10 CAGR PROJECTIONS 40
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 41
2.3 DATA TRIANGULATION APPROACH 43
FIGURE 12 DATA TRIANGULATION METHODOLOGY 43
2.4 MARKET SHARE ESTIMATION 44
2.5 ASSUMPTIONS FOR THE STUDY 44
2.6 RISK ASSESSMENT/LIMITATIONS 45
2.7 COVID-19 HEALTH ASSESSMENT 45
2.8 COVID-19 ECONOMIC ASSESSMENT 45
2.9 ASSESSING THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 46
FIGURE 13 CRITERIA IMPACTING THE GLOBAL ECONOMY 46
FIGURE 14 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 47

3 EXECUTIVE SUMMARY 48
FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION) 48
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION) 49
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2021 VS. 2026 (USD MILLION) 49
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 50

4 PREMIUM INSIGHTS 52
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW 52
FIGURE 19 RISING PET POPULATION TO DRIVE MARKET GROWTH 52
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2020) 53
FIGURE 20 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020 53
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 54
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2019–2026) 55
FIGURE 22 NORTH AMERICA WILL CONTINUE TO DOMINATE THE COMPANION ANIMAL PHARMACEUTICALS MARKET DURING THE FORECAST PERIOD 55
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. DEVELOPING MARKETS 55
FIGURE 23 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 55

5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
TABLE 2 COMPANION ANIMAL PHARMACEUTICALS MARKET: IMPACT ANALYSIS 56
5.2.1 MARKET DRIVERS 57
5.2.1.1 Growing prevalence of zoonotic diseases 57
TABLE 3 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2018) 57
5.2.1.2 Rising demand for pet insurance with growing animal health expenditure 58
FIGURE 24 US: PET EXPENDITURE, 2010-2019 (USD BILLION) 59
FIGURE 25 US: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION) 59
5.2.1.3 Growing investments by key players 60
5.2.1.4 Initiatives by various government agencies and animal associations 60
5.2.1.5 Growth in companion animal ownership rates 61
FIGURE 26 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP 62
5.2.2 MARKET RESTRAINTS 63
5.2.2.1 Rising pet care costs 63
5.2.2.2 Limited number of new product developments 63
5.2.2.3 High storage cost of vaccines 63
5.2.3 MARKET OPPORTUNITIES 64
5.2.3.1 Lucrative growth opportunities in emerging markets 64
5.2.3.2 Growing prevalence of animal diseases 65
5.2.3.3 Technological advancements in manufacturing vaccines 65
5.2.4 MARKET CHALLENGES 66
5.2.4.1 Stringent regulatory approval process for drugs 66
5.2.4.2 Inadequate surveillance and reporting systems of vaccines 66
5.2.4.3 Diversity of parasite species 66

6 INDUSTRY INSIGHTS 67
6.1 INTRODUCTION 67
6.2 INDUSTRY TRENDS 67
6.2.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTHCARE INDUSTRY 67
TABLE 4 MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017–2019) 68
6.2.2 INNOVATIONS IN ANIMAL HEALTHCARE PRODUCTS 68
TABLE 5 INNOVATIVE ANIMAL PHARMACEUTICAL TRENDS 69
6.3 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 69
6.3.1 THREAT OF NEW ENTRANTS 70
6.3.2 THREAT OF SUBSTITUTES 70
6.3.3 BARGAINING POWER OF SUPPLIERS 70
6.3.4 BARGAINING POWER OF BUYERS 71
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 71
6.4 REGULATORY ANALYSIS 71
FIGURE 27 DEVELOPMENT AND APPROVAL PROCESS FOR COMPANION ANIMAL PHARMACEUTICAL PRODUCTS 73
TABLE 7 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS 74
FIGURE 28 EUROPE: COMPANION ANIMAL PHARMACEUTICAL PRODUCTS APPROVAL PROCESS 75
6.5 VALUE CHAIN ANALYSIS 76
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS 77
6.6 SUPPLY CHAIN ANALYSIS 77
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS 79
6.7 ECOSYSTEM ANALYSIS 79
6.7.1 ECOSYSTEM ANALYSIS FOR THE COMPANION ANIMAL PHARMACEUTICALS MARKET 79
FIGURE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 80
6.8 IMPACT OF COVID-19 ON THE COMPANION ANIMAL PHARMACEUTICALS MARKET 80
6.9 PATENT ANALYSIS 81
6.9.1 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS 81
FIGURE 32 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020) 81
6.9.2 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS 82
FIGURE 33 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS PATENTS (2015–2020) 82
6.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS 83
FIGURE 34 TOP APPLICANT COUNTRIES FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020) 83

7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION 84
7.1 INTRODUCTION 85
TABLE 8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 85
7.2 INFECTIOUS DISEASES 85
TABLE 9 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 86
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 86
7.2.1 PARASITICIDES 87
7.2.1.1 Growing regulatory guidelines to prevent the spread of parasite-caused diseases is fueling the market growth 87
TABLE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2019–2026 (USD MILLION) 88
7.2.2 VACCINES 88
7.2.2.1 Rising awareness among pet owners for vaccinating dogs and cats to drive market growth 88
TABLE 12 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD MILLION) 90
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS 90
7.2.3.1 Antibiotics and antimicrobials help combat clinical and subclinical diseases in animals 90
TABLE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2019–2026 (USD MILLION) 91
7.2.4 OTHER COMPANION ANIMAL PHARMACEUTICALS 92
TABLE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMAL PHARMACEUTICALS, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.3 DERMATOLOGIC DISEASES 93
7.3.1 GROWING CASES OF DERMATOLOGIC DISEASES HAVE INCREASED THE DEMAND FOR VETERINARY PHARMACEUTICALS 93
TABLE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.4 PAIN 95
7.4.1 RISING PREVALENCE OF MUSCULOSKELETAL DISORDERS TO DRIVE SUPPORT MARKET GROWTH 95
TABLE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2019–2026 (USD MILLION) 96
7.5 ORTHOPEDIC DISEASES 96
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS AND THE INCREASING POPULATION OF OBESE PETS HAS INCREASED THE DEMAND FOR ORTHOPEDIC DRUGS 96
TABLE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 97
7.6 BEHAVIORAL DISORDERS 98
7.6.1 GROWING AWARENESS AMONG PET OWNERS REGARDING BEHAVIORAL DISORDERS IS EXPECTED TO FUEL THE DEMAND FOR THESE DRUGS 98
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 99
7.7 OTHER INDICATIONS 99
TABLE 19 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 101

8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE 102
8.1 INTRODUCTION 103
TABLE 20 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 103
8.2 DOGS 104
8.2.1 DOGS SEGMENT IS EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD 104
FIGURE 35 POPULATION OF PET DOGS IN INDIA (MILLION) 104
FIGURE 36 POPULATION OF PET DOGS GLOBALLY (MILLION) 105
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2019–2026 (USD MILLION) 106
8.3 CATS 106
8.3.1 GROWING RESEARCH ON FELINE HEALTH AND WELLBEING TO SUPPORT THE MARKET GROWTH 106
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2019–2026 (USD MILLION) 107
8.4 HORSES 108
8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES IN THE EQUINE POPULATION TO DRIVE MARKET GROWTH 108
TABLE 23 HORSE POPULATION, BY REGION, 2016–2019 (MILLION) 108
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2019–2026 (USD MILLION) 109
8.5 OTHER COMPANION ANIMALS 110
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION) 110

9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 111
9.1 INTRODUCTION 112
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 112
9.2 VETERINARY HOSPITALS 112
9.2.1 VETERINARY HOSPITALS ARE THE LARGEST AND FASTEST-GROWING SEGMENT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 112
TABLE 27 VETERINARY VISIT EXPENSES FOR CATS AND DOGS IN THE US 113
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION) 113
9.3 VETERINARY CLINICS 114
9.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH 114
TABLE 29 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2015 VS. 2019 115
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2019–2026 (USD MILLION) 116
9.4 RETAIL PHARMACIES 116
9.4.1 EASY ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTION AND OTC TO SUPPORT THE MARKET GROWTH 116
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019–2026 (USD MILLION) 117

10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION 118
10.1 INTRODUCTION 119
TABLE 32 COMPANION ANIMAL POPULATION, BY COUNTRY, 2020 (THOUSAND) 119
FIGURE 37 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT 120
TABLE 33 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2019–2026 (USD MILLION) 120
10.2 NORTH AMERICA 121
FIGURE 38 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA 121
FIGURE 39 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 122
TABLE 34 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 35 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 123
TABLE 36 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 37 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 123
TABLE 38 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 124
10.2.1 US 124
10.2.1.1 The US dominates the North American companion animal pharmaceuticals market 124
FIGURE 40 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION) 124
TABLE 39 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018 125
TABLE 40 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 125
TABLE 41 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 42 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 126
TABLE 43 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 126
10.2.2 CANADA 127
10.2.2.1 Increasing pet adoption rate and rising animal health awareness to support market growth in Canada 127
TABLE 44 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 127
TABLE 45 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 46 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 128
TABLE 47 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 128
10.3 EUROPE 129
TABLE 48 EUROPE: NUMBER OF VETERINARIANS, 2012–2018 129
TABLE 49 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 50 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 130
TABLE 51 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 130
TABLE 52 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 131
TABLE 53 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 131
10.3.1 GERMANY 131
10.3.1.1 Germany held the largest share of the European market in 2020 131
TABLE 54 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION) 132
TABLE 55 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 132
TABLE 56 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 57 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 133
TABLE 58 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 133
10.3.2 UK 133
10.3.2.1 Growing pet ownership rates to drive market growth 133
TABLE 59 UK: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION) 134
TABLE 60 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 134
TABLE 61 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 62 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 135
TABLE 63 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 135
10.3.3 FRANCE 136
10.3.3.1 Presence of major players in the country is expected to propel the companion animal pharmaceuticals market 136
TABLE 64 FRANCE: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION) 136
TABLE 65 FRANCE: NUMBER OF VETERINARIANS, 2014 VS. 2016 VS. 2018 137
TABLE 66 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 137
TABLE 67 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 68 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 138
TABLE 69 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 138
10.3.4 SPAIN 139
10.3.4.1 Increasing animal health expenditure is propelling market growth in Spain 139
TABLE 70 SPAIN: COMPANION ANIMAL POPULATION, 2014–2018 (MILLION) 139
TABLE 71 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 139
TABLE 72 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 73 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 140
TABLE 74 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 140
10.3.5 ITALY 141
10.3.5.1 Growing animal healthcare expenditure to support market growth 141
TABLE 75 ITALY: COMPANION ANIMAL POPULATION, 2016–2018 (MILLION) 141
TABLE 76 ITALY: NUMBER OF VETERINARIANS, 2016 VS. 2019 141
TABLE 77 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 142
TABLE 78 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 79 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 142
TABLE 80 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 143
10.3.6 REST OF EUROPE 143
TABLE 81 ROE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION) 143
TABLE 82 COMPANION ANIMAL POPULATION IN THE REST OF EUROPE, 2019 (MILLION) 144
TABLE 83 ROE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2016 VS. 2019 144
TABLE 84 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 144
TABLE 85 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 86 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 145
TABLE 87 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 145
10.4 ASIA PACIFIC 146
FIGURE 41 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 147
TABLE 88 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 148
TABLE 89 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 148
TABLE 90 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 91 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 149
TABLE 92 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 149
10.4.1 CHINA 149
10.4.1.1 China dominates the companion animal pharmaceuticals market 149
FIGURE 42 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 150
TABLE 93 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 150
TABLE 94 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 95 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 151
TABLE 96 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 151
10.4.2 JAPAN 152
10.4.2.1 Rising demand for imported breeds is driving pet adoption rates in the country 152
TABLE 97 JAPAN: NUMBER OF VETERINARIANS, 2016 VS. 2019 152
TABLE 98 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 153
TABLE 99 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 100 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 153
TABLE 101 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 154
10.4.3 INDIA 154
10.4.3.1 India is an untapped market with large growth potential in companion animal pharmaceuticals 154
FIGURE 43 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 155
TABLE 102 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 155
TABLE 103 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 104 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 156
TABLE 105 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 156
10.4.4 SOUTH KOREA 157
10.4.4.1 Rising pet population and growing awareness about animal health to support market growth 157
TABLE 106 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 158
TABLE 107 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 108 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 158
TABLE 109 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 159
10.4.5 REST OF ASIA PACIFIC 159
FIGURE 44 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 160
TABLE 110 ROAPAC: NUMBER OF VETERINARIANS, 2012−2019 160
TABLE 111 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 161
TABLE 112 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 113 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 161
TABLE 114 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 162
10.5 LATIN AMERICA 162
10.5.1 RISING POOL OF SKILLED VETERINARIANS AND GROWING PET HEALTH EXPENDITURE TO DRIVE THE MARKET GROWTH 162
TABLE 115 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICAN COUNTRIES, 2016 VS. 2019 163
TABLE 116 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 163
TABLE 117 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 118 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 164
TABLE 119 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 164
10.6 MIDDLE EAST & AFRICA 165
10.6.1 GROWING POPULATION OF COMPANION ANIMALS TO PROPEL MARKET GROWTH 165
TABLE 120 AFRICA: NUMBER OF VETERINARIANS, 2012 VS. 2017 VS. 2019 166
TABLE 121 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 166
TABLE 122 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 123 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 167
TABLE 124 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 167

11 COMPETITIVE LANDSCAPE 168
11.1 OVERVIEW 168
11.2 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO FEBRUARY 2021 169
11.3 GEOGRAPHICAL FOOTPRINT OF THE MAJOR PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET 170
FIGURE 45 GEOGRAPHIC REVENUE MIX: COMPANION ANIMAL PHARMACEUTICALS MARKET (2020) 170
11.4 COMPANY PRODUCT FOOTPRINT 170
FIGURE 46 PRODUCT PORTFOLIO ANALYSIS: COMPANION ANIMAL PHARMACEUTICALS MARKET 171
11.5 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS 171
FIGURE 47 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2015–2019) 172
11.6 MARKET SHARE ANALYSIS 172
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2020 173
11.7 MARKET EVALUATION FRAMEWORK 174
FIGURE 49 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY 174
11.8 COMPETITIVE LEADERSHIP MAPPING 175
11.8.1 STARS 175
11.8.2 EMERGING LEADERS 175
11.8.3 PERVASIVE PLAYERS 176
11.8.4 PARTICIPANTS 176
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
11.9 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS 178
11.9.1 PROGRESSIVE COMPANIES 178
11.9.2 DYNAMIC COMPANIES 178
11.9.3 STARTING BLOCKS 178
11.9.4 RESPONSIVE COMPANIES 178
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 179
11.10 COMPETITIVE SITUATION AND TRENDS 180
11.10.1 PRODUCT LAUNCHES & APPROVALS 180
TABLE 125 PRODUCT LAUNCHES & APPROVALS 180
11.10.2 EXPANSIONS 181
TABLE 126 EXPANSIONS 181
11.10.3 ACQUISITIONS 182
TABLE 127 ACQUISITIONS 182
11.10.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 183
TABLE 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 183

12 COMPANY PROFILES 185
12.1 KEY PLAYERS 185
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1.1 ZOETIS INC. 185
TABLE 129 ZOETIS INC.: BUSINESS OVERVIEW 185
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2020) 186
12.1.2 MERCK & CO., INC. 190
TABLE 130 MERCK & CO., INC.: BUSINESS OVERVIEW 190
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2020) 191
12.1.3 BOEHRINGER INGELHEIM GMBH 194
TABLE 131 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW 194
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019) 194
12.1.4 ELANCO ANIMAL HEALTH INCORPORATED 198
TABLE 132 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW 198
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2019) 199
12.1.5 CEVA SANTÉ ANIMALE 203
TABLE 133 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW 203
12.1.6 VIRBAC 205
TABLE 134 VIRBAC: BUSINESS OVERVIEW 205
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2019) 205
12.1.7 VETOQUINOL S.A. 208
TABLE 135 VETOQUINOL S.A.: BUSINESS OVERVIEW 208
FIGURE 57 VETOQUINOL S.A.: COMPANY SNAPSHOT (2019) 208
12.1.8 DECHRA PHARMACEUTICALS PLC 211
TABLE 136 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW 211
FIGURE 58 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019) 212
12.1.9 CHANELLE PHARMA 215
TABLE 137 CHANELLE PHARMA: BUSINESS OVERVIEW 215
12.1.10 KYORITSU SEIYAKU 217
TABLE 138 KYORITSU SEIYAKU: BUSINESS OVERVIEW 217
12.1.11 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED 219
TABLE 139 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: BUSINESS OVERVIEW 219
FIGURE 59 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: COMPANY SNAPSHOT (2019) 219
12.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 221
TABLE 140 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 221
12.1.13 HIPRA 222
TABLE 141 HIPRA: BUSINESS OVERVIEW 222
12.1.14 NORBROOK HOLDINGS LIMITED 223
TABLE 142 NORBROOK HOLDINGS LIMITED: BUSINESS OVERVIEW 223
12.1.15 INOVET 225
TABLE 143 INOVET: BUSINESS OVERVIEW 225
12.2 OTHER PLAYERS 227
12.2.1 ENDOVAC ANIMAL HEALTH 227
12.2.2 ECO ANIMAL HEALTH GROUP PLC 227
12.2.3 INDIAN IMMUNOLOGICALS LTD. 228
12.2.4 ASHISH LIFE SCIENCE PVT. LTD. 229
12.2.5 LUTIM PHARMA PVT. LTD. 230
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 231
13.1 INSIGHTS FROM INDUSTRY EXPERTS 231
13.2 DISCUSSION GUIDE 232
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235
13.4 AVAILABLE CUSTOMIZATIONS 237
13.5 RELATED REPORTS 237
13.6 AUTHOR DETAILS 238



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の伴侶動物用医薬品市場(~2026年):疾患別(感染症、抗生物質、寄生虫駆除剤、ワクチン、疼痛)、動物種類別(犬、猫、馬)、流通チャネル別(動物病院、クリニック)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆